Silence Therapeutics (NASDAQ:SLN) Given New $55.00 Price Target at Chardan Capital

Silence Therapeutics (NASDAQ:SLN) had its price objective boosted by Chardan Capital from $42.00 to $55.00 in a report released on Friday, Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research firms have also recently weighed in on SLN. HC Wainwright reissued a buy rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Thursday. Morgan Stanley reissued an overweight rating and set a $45.00 price target on shares of Silence Therapeutics in a report on Monday, April 22nd.

Silence Therapeutics Price Performance

SLN stock opened at $19.00 on Friday. Silence Therapeutics has a 12-month low of $4.84 and a 12-month high of $27.72. The stock’s 50 day simple moving average is $21.15 and its 200 day simple moving average is $20.95.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings data on Thursday, May 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.18. The business had revenue of $15.73 million for the quarter, compared to analysts’ expectations of $4.53 million. Silence Therapeutics had a negative return on equity of 79.90% and a negative net margin of 131.44%. As a group, equities research analysts anticipate that Silence Therapeutics will post -1.52 earnings per share for the current year.

Institutional Investors Weigh In On Silence Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SLN. SG Americas Securities LLC purchased a new stake in shares of Silence Therapeutics in the 4th quarter worth $110,000. Vivo Capital LLC purchased a new stake in shares of Silence Therapeutics in the 4th quarter worth $8,862,000. Parkman Healthcare Partners LLC increased its stake in shares of Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,063 shares in the last quarter. Redmile Group LLC purchased a new stake in shares of Silence Therapeutics in the 1st quarter worth $43,798,000. Finally, Janus Henderson Group PLC purchased a new stake in Silence Therapeutics in the 1st quarter worth $13,575,000. 98.73% of the stock is currently owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.